<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Many of the effects of <z:chebi fb="0" ids="27881">resveratrol</z:chebi> are consistent with the activation of <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK), silent information regulator T1 (SIRT1) and peroxisome proliferator-activated receptor (PPAR)γ co-activator 1α (<z:chebi fb="6" ids="26336">PGC</z:chebi>-1α), which play key roles in the regulation of <z:chebi fb="23" ids="18059">lipid</z:chebi> and <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis, and in the control of <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether <z:chebi fb="0" ids="27881">resveratrol</z:chebi> has protective effects on the kidney in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Four groups of male C57BLKS/J db/m and db/db mice were used in this study </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi> was administered via gavage to diabetic and non-diabetic mice, starting at 8 weeks of age, for 12 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The db/db mice treated with <z:chebi fb="0" ids="27881">resveratrol</z:chebi> had decreased <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi> ameliorated glomerular matrix expansion and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi> also lowered the NEFA and triacylglycerol content of the kidney, and this action was related to increases in the phosphorylation of AMPK and the activation of SIRT1-<z:chebi fb="6" ids="26336">PGC</z:chebi>-1α signalling and of the key downstream effectors, the PPARα-<z:chebi fb="67" ids="50114">oestrogen</z:chebi>-related receptor (ERR)-1α-<z:chebi fb="0" ids="15889">sterol</z:chebi> regulatory element-binding protein 1 (SREBP1) </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, <z:chebi fb="0" ids="27881">resveratrol</z:chebi> decreased the activity of phosphatidylinositol-3 kinase (PI3K)-Akt phosphorylation and class O forkhead box (FOXO)3a phosphorylation, which resulted in a decrease in B cell <z:mpath ids='MPATH_336'>leukaemia</z:mpath>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> 2 (BCL-2)-associated X protein (BAX) and increases in BCL-2, <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD)1 and SOD2 production </plain></SENT>
<SENT sid="8" pm="."><plain>Consequently, <z:chebi fb="0" ids="27881">resveratrol</z:chebi> reversed the increase in renal apoptotic cells and <z:mp ids='MP_0003674'>oxidative stress</z:mp>, as reflected by renal 8-hydroxy-deoxyguanosine (8-OH-dG), urinary 8-OH-dG and isoprostane concentrations </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi> prevented high-<z:chebi fb="105" ids="17234">glucose</z:chebi>-induced <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in cultured mesangial cells through the phosphorylation of AMPK and activation of SIRT1-<z:chebi fb="6" ids="26336">PGC</z:chebi>-1α signalling and the downstream effectors, PPARα-ERR-1α-SREBP1 </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: The results suggest that <z:chebi fb="0" ids="27881">resveratrol</z:chebi> prevents diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in db/db mice by the phosphorylation of AMPK and activation of SIRT1-<z:chebi fb="6" ids="26336">PGC</z:chebi>-1α signalling, which appear to prevent lipotoxicity-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0003674'>oxidative stress</z:mp> in the kidney </plain></SENT>
</text></document>